UK pharmacies warn that patients are using AI-edited photos and tricks like pocket weights to bypass BMI eligibility rules for weight-loss drugs such as Mounjaro and Wegovy. With an estimated 1.6 million UK adults accessing GLP-1s, experts highlight severe health risks for individuals with eating disorders. The General Pharmaceutical Council mandates independent verification and warns of enforcement action against non-compliant prescribers.
Use and detection of AI-Edited photos
- ▪Ahsan Bhatti of Quick Meds stated that AI-manipulated patient photos often exhibit tell-tale signs such as curved door frames or inconsistent shadows and lighting.
- ▪Patients are using AI-edited photographs and physical tricks like hiding weights in pockets to appear heavier and gain access to weight-loss treatments.
Quick Meds pharmacy warnings
- ▪Quick Meds owner Ahsan Bhatti warned that GLP-1 drugs are powerful prescription medicines carrying potential risks and side-effects rather than cosmetic quick fixes.
- ▪Quick Meds owner Ahsan Bhatti stressed the importance of educating patients about the potentially life-threatening consequences of obtaining prescription medicines through deception.
Eating disorder warnings
- ▪Kerri Fleming of eating disorder charity Beat stated that safeguards such as requiring live photographs are not yet implemented by every pharmacy.
- ▪The eating disorder faculty of the Royal College of Psychiatrists and charity Beat warned that patients with eating disorders misuse weight-loss drugs using unverified AI-falsified photos.
Eligibility criteria for weight-loss treatments
- ▪Private providers in England can prescribe weight-loss injections to patients with a BMI of 30 or above, falling to 27 with a weight-related condition.
- ▪Adults in England qualify for National Health Service weight-loss treatments with a body mass index of 35 or above and at least one weight-related health condition.
GLP-1 medication market
- ▪A University College London study estimated that 1.6 million UK adults used GLP-1 medications in a 12-month period to early 2025, primarily through private online pharmacies charging £300 monthly.
- ▪Mounjaro, produced by Eli Lilly, and Wegovy, produced by Novo Nordisk, dominate the UK market for GLP-1 weight-loss medications.
Regulatory rules on patient verification
- ▪General Pharmaceutical Council chief pharmacy officer Roz Gittins stated that relying solely on photos, phone calls, or pre-recorded videos is not appropriate for weight-management prescribing.
- ▪The General Pharmaceutical Council warned it has the power to take enforcement action against pharmacists failing to independently verify a patient's weight, height, or BMI.
- ▪Guidelines introduced nearly two years ago require pharmacies to verify weight-loss drug patients through medical record checks or video consultations.
Story comments
Loading comments…